How to buy Capricor Therapeutics shares

Own Capricor Therapeutics shares in just a few minutes.

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Capricor Therapeutics, Inc is a biotechnology business with stocks listed in the US. Capricor Therapeutics shares (CAPR) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$3.86 – an increase of 1.85% over the previous week. Here's how to invest if you're based in Australia.

How to buy shares in Capricor Therapeutics

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Capricor Therapeutics. Find the share by name or ticker symbol: CAPR. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Capricor Therapeutics reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$3.86, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Capricor Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Capricor Therapeutics. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Capricor Therapeutics share price

Use our graph to track the performance of CAPR stocks over time.

Capricor Therapeutics shares at a glance

Information last updated 2021-06-09.
52-week rangeUS$3.13 - US$12.32
50-day moving average US$3.846
200-day moving average US$4.8023
Target priceUS$10.5
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) US$-3.736

Compare share trading platforms to buy stock

Name Product Standard brokerage for US shares Inactivity fee Currency conversion fee Markets
eToro Share Trading (US stocks)
US$0
US$10 per month if there’s been no login for 12 months
0.50%
US shares, ETFs
Zero brokerage share trading on US stocks with trades as low as $50.
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
Finder Award
IG Share Trading
US$0
$50 per quarter if you make fewer than three trades in that period
0.70%
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Saxo Capital Markets (Classic account)
US$9.9
No
0.75%
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, ETFs
Acess 19,000+ stocks on 37 exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
CMC Markets Stockbroking
US$0
No
0.60%
ASX shares, Global shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges.
loading

Compare up to 4 providers

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Capricor Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Capricor Therapeutics price performance over time

Historical closes compared with the last close of $3.86

1 week (2021-06-03) -1.03%
1 month (2021-05-13) 22.15%
3 months (2021-03-12) -25.48%
6 months (2020-12-11) -8.10%
1 year (2020-06-12) -13.06%
2 years (2019-06-13) 6.34%
3 years (2018-06-13) -73.01%
5 years (2016-06-13) -88.68%

Capricor Therapeutics financials

Revenue TTM US$165,373
Gross profit TTM US$-8,146,750
Return on assets TTM -36.19%
Return on equity TTM -72.76%
Profit margin 0%
Book value 1.596
Market capitalisation US$103 million

TTM: trailing 12 months

Shorting Capricor Therapeutics shares

There are currently 1.7 million Capricor Therapeutics shares held short by investors – that's known as Capricor Therapeutics's "short interest". This figure is 1% down from 1.8 million last month.

There are a few different ways that this level of interest in shorting Capricor Therapeutics shares can be evaluated.

Capricor Therapeutics's "short interest ratio" (SIR)

Capricor Therapeutics's "short interest ratio" (SIR) is the quantity of Capricor Therapeutics shares currently shorted divided by the average quantity of Capricor Therapeutics shares traded daily (recently around 735722.03389831). Capricor Therapeutics's SIR currently stands at 2.36. In other words for every 100,000 Capricor Therapeutics shares traded daily on the market, roughly 2360 shares are currently held short.

However Capricor Therapeutics's short interest can also be evaluated against the total number of Capricor Therapeutics shares, or, against the total number of tradable Capricor Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Capricor Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Capricor Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.0785% of the tradable shares (for every 100,000 tradable Capricor Therapeutics shares, roughly 79 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Capricor Therapeutics.

Find out more about how you can short Capricor Therapeutics stock.

Capricor Therapeutics share dividends

We're not expecting Capricor Therapeutics to pay a dividend over the next 12 months.

Have Capricor Therapeutics's shares ever split?

Capricor Therapeutics's shares were split on a 1:10 basis on 4 June 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Capricor Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Capricor Therapeutics shares which in turn could have impacted Capricor Therapeutics's share price.

Capricor Therapeutics share price volatility

Over the last 12 months, Capricor Therapeutics's shares have ranged in value from as little as US$3.13 up to US$12.32. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Capricor Therapeutics's is 6.4598. This would suggest that Capricor Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Capricor Therapeutics overview

Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase II clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with COVID-19; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in preclinical stage for the potential prevention of COVID-19. Capricor collaborates with Lonza Houston, Inc. for the development of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in Beverly Hills, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site
Not sure what platform to go with?
Take this quick quiz to find the right share trading platform